Palbociclib - Revision history

http://52.214.119.220/wiki/index.php?action=history&feed=atom&title=Palbociclib Palbociclib - Revision history 2026-04-07T12:13:33Z Revision history for this page on the wiki MediaWiki 1.11.2 http://52.214.119.220/wiki/index.php?title=Palbociclib&diff=4020266&oldid=prev Michal Harel at 08:54, 21 January 2024 2024-01-21T08:54:03Z

<p></p> <table style="background-color: white; color:black;"> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr> <td colspan='2' style="background-color: white; color:black;">←Older revision</td> <td colspan='2' style="background-color: white; color:black;">Revision as of 08:54, 21 January 2024</td> </tr> <tr><td colspan="2" class="diff-lineno">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='<del style="color: red; font-weight: bold; text-decoration: none;">Caption for this structure</del>' scene='10/1001138/Cv/1'></div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='<ins style="color: red; font-weight: bold; text-decoration: none;">Palbociclib</ins>' scene='10/1001138/Cv/1'></div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> </div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> </div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> </table>

Michal Harel http://52.214.119.220/wiki/index.php?title=Palbociclib&diff=3908373&oldid=prev Alexander Berchansky at 12:20, 12 October 2023 2023-10-12T12:20:43Z

<p></p> <table style="background-color: white; color:black;"> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr> <td colspan='2' style="background-color: white; color:black;">←Older revision</td> <td colspan='2' style="background-color: white; color:black;">Revision as of 12:20, 12 October 2023</td> </tr> <tr><td colspan="2" class="diff-lineno">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'></div></td></tr> <tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> <del style="color: red; font-weight: bold; text-decoration: none;">See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</del></div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer<ins style="color: red; font-weight: bold; text-decoration: none;">. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]</ins>. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> </div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>In the G1 phase of the cell cycle, mammalian cells must pass a checkpoint, known as the restriction point "R", in order to complete the cell cycle and divide. CDK4 and CDK6 complex with cyclin D drive the phosphorylation of the retinoblastoma protein, Rb, which allows the cell to pass R and commit to division. Regulation of one or more proteins involved in this checkpoint is lost in many cancers. However, by inhibiting CDK4/6, palbociclib ensures that the cyclin D-CDK4/6 complex cannot aid in phosphorylating Rb. This prevents the cell from passing R and exiting G1, and in turn from proceeding through the cell cycle.<ref name="a5">PMID:28438180</ref></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>In the G1 phase of the cell cycle, mammalian cells must pass a checkpoint, known as the restriction point "R", in order to complete the cell cycle and divide. CDK4 and CDK6 complex with cyclin D drive the phosphorylation of the retinoblastoma protein, Rb, which allows the cell to pass R and commit to division. Regulation of one or more proteins involved in this checkpoint is lost in many cancers. However, by inhibiting CDK4/6, palbociclib ensures that the cyclin D-CDK4/6 complex cannot aid in phosphorylating Rb. This prevents the cell from passing R and exiting G1, and in turn from proceeding through the cell cycle.<ref name="a5">PMID:28438180</ref></div></td></tr> </table>

Alexander Berchansky http://52.214.119.220/wiki/index.php?title=Palbociclib&diff=3908372&oldid=prev Alexander Berchansky at 12:19, 12 October 2023 2023-10-12T12:19:55Z

<p></p> <table style="background-color: white; color:black;"> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr> <td colspan='2' style="background-color: white; color:black;">←Older revision</td> <td colspan='2' style="background-color: white; color:black;">Revision as of 12:19, 12 October 2023</td> </tr> <tr><td colspan="2" class="diff-lineno">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'></div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>In the G1 phase of the cell cycle, mammalian cells must pass a checkpoint, known as the restriction point "R", in order to complete the cell cycle and divide. CDK4 and CDK6 complex with cyclin D drive the phosphorylation of the retinoblastoma protein, Rb, which allows the cell to pass R and commit to division. Regulation of one or more proteins involved in this checkpoint is lost in many cancers. However, by inhibiting CDK4/6, palbociclib ensures that the cyclin D-CDK4/6 complex cannot aid in phosphorylating Rb. This prevents the cell from passing R and exiting G1, and in turn from proceeding through the cell cycle.<ref name="a5">PMID:28438180</ref></div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><scene name='10/1001138/Overall/3'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><scene name='10/1001138/Overall/3'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).</div></td></tr> </table>

Alexander Berchansky http://52.214.119.220/wiki/index.php?title=Palbociclib&diff=3908362&oldid=prev Alexander Berchansky at 10:48, 11 October 2023 2023-10-11T10:48:38Z

<p></p> <table style="background-color: white; color:black;"> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr> <td colspan='2' style="background-color: white; color:black;">←Older revision</td> <td colspan='2' style="background-color: white; color:black;">Revision as of 10:48, 11 October 2023</td> </tr> <tr><td colspan="2" class="diff-lineno">Line 2:</td> <td colspan="2" class="diff-lineno">Line 2:</td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div><scene name='10/1001138/Overall/<del style="color: red; font-weight: bold; text-decoration: none;">1</del>'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><scene name='10/1001138/Overall/<ins style="color: red; font-weight: bold; text-decoration: none;">3</ins>'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><scene name='10/1001138/Binding_site/1'>Palbociclib binding site</scene>.</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><scene name='10/1001138/Binding_site/1'>Palbociclib binding site</scene>.</div></td></tr> </table>

Alexander Berchansky http://52.214.119.220/wiki/index.php?title=Palbociclib&diff=3908361&oldid=prev Alexander Berchansky at 10:46, 11 October 2023 2023-10-11T10:46:49Z

<p></p> <table style="background-color: white; color:black;"> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr> <td colspan='2' style="background-color: white; color:black;">←Older revision</td> <td colspan='2' style="background-color: white; color:black;">Revision as of 10:46, 11 October 2023</td> </tr> <tr><td colspan="2" class="diff-lineno">Line 3:</td> <td colspan="2" class="diff-lineno">Line 3:</td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><scene name='10/1001138/Overall/1'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><scene name='10/1001138/Overall/1'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]]).</div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><scene name='10/1001138/Binding_site/1'>Palbociclib binding site</scene>.</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div></StructureSection></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div></StructureSection></div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>== References ==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>== References ==</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><references/></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><references/></div></td></tr> </table>

Alexander Berchansky http://52.214.119.220/wiki/index.php?title=Palbociclib&diff=3908360&oldid=prev Alexander Berchansky at 10:34, 11 October 2023 2023-10-11T10:34:55Z

<p></p> <table style="background-color: white; color:black;"> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr> <td colspan='2' style="background-color: white; color:black;">←Older revision</td> <td colspan='2' style="background-color: white; color:black;">Revision as of 10:34, 11 October 2023</td> </tr> <tr><td colspan="2" class="diff-lineno">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'></div></td></tr> <tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]). <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]<ins style="color: red; font-weight: bold; text-decoration: none;">.</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><ins style="color: red; font-weight: bold; text-decoration: none;"><scene name='10/1001138/Overall/1'>The X-ray co-crystal structure of human CDK6 and Palbociclib</scene> ([[5l2i]])</ins>.</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div></StructureSection></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div></StructureSection></div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>== References ==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>== References ==</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><references/></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><references/></div></td></tr> </table>

Alexander Berchansky http://52.214.119.220/wiki/index.php?title=Palbociclib&diff=3908357&oldid=prev Alexander Berchansky at 10:26, 11 October 2023 2023-10-11T10:26:33Z

<p></p> <table style="background-color: white; color:black;"> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr> <td colspan='2' style="background-color: white; color:black;">←Older revision</td> <td colspan='2' style="background-color: white; color:black;">Revision as of 10:26, 11 October 2023</td> </tr> <tr><td colspan="2" class="diff-lineno">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'></div></td></tr> <tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 <ins style="color: red; font-weight: bold; text-decoration: none;">(see also [[CDK4]])</ins>. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div></StructureSection></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div></StructureSection></div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>== References ==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>== References ==</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><references/></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><references/></div></td></tr> </table>

Alexander Berchansky http://52.214.119.220/wiki/index.php?title=Palbociclib&diff=3908355&oldid=prev Alexander Berchansky at 10:24, 11 October 2023 2023-10-11T10:24:16Z

<p></p> <table style="background-color: white; color:black;"> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr> <td colspan='2' style="background-color: white; color:black;">←Older revision</td> <td colspan='2' style="background-color: white; color:black;">Revision as of 10:24, 11 October 2023</td> </tr> <tr><td colspan="2" class="diff-lineno">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'></div></td></tr> <tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the <ins style="color: red; font-weight: bold; text-decoration: none;">[[</ins>cyclin-dependent kinases<ins style="color: red; font-weight: bold; text-decoration: none;">]] </ins>CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div></StructureSection></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div></StructureSection></div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>== References ==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>== References ==</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><references/></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><references/></div></td></tr> </table>

Alexander Berchansky http://52.214.119.220/wiki/index.php?title=Palbociclib&diff=3908354&oldid=prev Alexander Berchansky at 10:22, 11 October 2023 2023-10-11T10:22:07Z

<p></p> <table style="background-color: white; color:black;"> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr> <td colspan='2' style="background-color: white; color:black;">←Older revision</td> <td colspan='2' style="background-color: white; color:black;">Revision as of 10:22, 11 October 2023</td> </tr> <tr><td colspan="2" class="diff-lineno">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''></div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='<ins style="color: red; font-weight: bold; text-decoration: none;">10/1001138/Cv/1</ins>'></div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> </table>

Alexander Berchansky http://52.214.119.220/wiki/index.php?title=Palbociclib&diff=3908351&oldid=prev Alexander Berchansky at 10:18, 11 October 2023 2023-10-11T10:18:40Z

<p></p> <table style="background-color: white; color:black;"> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr> <td colspan='2' style="background-color: white; color:black;">←Older revision</td> <td colspan='2' style="background-color: white; color:black;">Revision as of 10:18, 11 October 2023</td> </tr> <tr><td colspan="2" class="diff-lineno">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''></div></td></tr> <tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. <ins style="color: red; font-weight: bold; text-decoration: none;"><ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> </ins>See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib].</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div></StructureSection></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div></StructureSection></div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>== References ==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>== References ==</div></td></tr> <tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><references/></div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div><references/></div></td></tr> </table>

Alexander Berchansky